Resource data sheet
DNA Bank Top

CSII-EF-MCS-IRES2-hKO1 (#RDB07915)

Backbone vector plasmid of lentivirus construct driven by EF-1 alpha promoter with hKO1 fluorescent protein marker.


Drawn by SnapGene® software
Sequence information
(Assembled from experimentally sequenced data)		 GenBank Flat File Format open
SnapGene file download
Publication Unpublished bioresource
Test sheet Data Sheet open 
 
Clone info. Backbone vector plasmid of lentivirus construct driven by EF-1 alpha promoter with hKO1 fluorescent protein marker.
Comment pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394) are popular choices for lentivirus packaging.
Vector backbone CSII-EF-MCS (RDB04378) ()
Selectable markers Ampicillin (E. coli). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Depositor|Developer Miyoshi, Hiroyuki |

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Ordering instruction.[link] 
Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer.
Additional terms and conditions:
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).

Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product.
Remarks ((Remarks)) Remember that you will be working with samples containing infectious virus.
Please contact us. We will provide you with appropriate documents.
Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件 本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。
付加的使用条件：
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).

InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。
備考 【使用上の注意】このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。
ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。

Catalog # Resource name Shipping form Fee
RDB07915 CSII-EF-MCS-IRES2-hKO1 Please contact us.

Ordering instruction of plasmids [in Japanese] [in English]

How to cite this biological resource

Materials & Methods section:

The CSII-EF-MCS-IRES2-hKO1 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07915).

Reference section:

Further references such as user reports and related articles (go to bottom)

References

Original, user report and related articles

user_report Matsuo, M., Protocol for generating a pancreatic cancer organoid associated with heterogeneous tumor microenvironment. STAR Protoc. 6 (1): 103539 (2025). PMID 39772386. [PubMed] [Article] [RRC of NBRP]
user_report Nakao, F., Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance. Leukemia 37 (5): 1028-1038 (2023). PMID 36973350. [PubMed] [Article] [RRC of NBRP]
user_report Takeuchi, K., Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. Cell Rep. 42 (11): 113420 (2023). PMID 37955987. [PubMed] [Article] [RRC of NBRP]
user_report Morita, K., Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell 181 (3): 702-715.e20 (2020). PMID 32315619. [PubMed] [Article] [RRC of NBRP]
user_report Morita, K., Genetic regulation of the RUNX transcription factor family has antitumor effects. J. Clin. Invest. 127 (7): 2815-2828 (2017). PMID 28530640. [PubMed] [Article] [RRC of NBRP]
user_report Morita, K., Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells. Sci. Rep. 7 (1): 16604 (2017). PMID 29192243. [PubMed] [Article] [RRC of NBRP]
user_report Morita, K., Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions. Blood Adv. 1: 1440-1451 (2017). PMID 29296785. [PubMed] [Article] [RRC of NBRP]
user_report Lee, J., Genetic reconstruction of mouse spermatogonial stem cell self-renewal in vitro by Ras-cyclin D2 activation. Cell Stem. Cell, 5, 76-86 (2009). PMID 19570516. [PubMed] [Article] [RRC of NBRP]